Russell Frank Company’s BioMarin Pharmaceuticals BMRN Stock Holding History

Russell Frank Company’s Portfolio BMRN Stock Details BMRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q1	$1.81M	Sell	21,938 -6,622	-23%	-$539K	﹤0.01%	1903
2015 Q4	$3.02M	Sell	28,560 -22,535	-44%	-$2.35M	0.01%	1576
2015 Q3	$5.38M	Sell	51,095 -4,578	-8%	-$612K	0.01%	1229
2015 Q2	$7.62M	Buy	55,673 +28,912	+108%	+$3.58M	0.01%	1169
2015 Q1	$3.33M	Buy	26,761 +4,342	+19%	+$460K	0.01%	1482
2014 Q4	$2.02M	Buy	22,419 +5,931	+36%	+$493K	﹤0.01%	1787
2014 Q3	$1.19M	Buy	16,488 +6,783	+70%	+$446K	﹤0.01%	1982
2014 Q2	$604K	Sell	9,705 -1,975	-17%	-$119K	﹤0.01%	2264
2014 Q1	$797K	Sell	11,680 -61,691	-84%	-$4.55M	﹤0.01%	2186
2013 Q4	$5.09M	Sell	73,371 -11,790	-14%	-$801K	0.01%	1228
2013 Q3	$6.15M	Sell	85,161 -73,880	-46%	-$4.91M	0.01%	1188
2013 Q2	$8.87M	Buy	+159,041	New	+$9.91M	0.02%	917

Other funds holding BMRN

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Sands Capital Management Arlington, Virginia $26.9B AUM 34.44% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Russell Frank Company's BMRN Position: Q1 2016 in Review

Russell Frank Company reduced its BioMarin Pharmaceuticals (BMRN) stake by 23% in Q1 2016, selling an estimated $539K and leaving 21,938 shares worth $1.81M. The position accounts for ﹤0.01% of the portfolio, ranked #1903.

Russell Frank Company first reported a position in BMRN in Q2 2013 and has held it in 12 quarters since. The position peaked at $8.87M in Q2 2013. 391 funds tracked by Wall St. Rank hold BMRN as of Q1 2016.

Russell Frank Company held 21,938 shares of BioMarin Pharmaceuticals worth $1.81M as of Q1 2016.
Russell Frank Company sold 6,622 BioMarin Pharmaceuticals shares in Q1 2016, an estimated $539K.
BioMarin Pharmaceuticals made up ﹤0.01% of Russell Frank Company's portfolio in Q1 2016, its #1903 holding.
Russell Frank Company first reported a position in BioMarin Pharmaceuticals in Q2 2013 and has held it in 12 quarters since.
Russell Frank Company's BioMarin Pharmaceuticals position peaked at $8.87M in Q2 2013.
391 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q1 2016.

Based on Russell Frank Company's 13F filing for Q1 2016, filed 29 Apr 2016.